SANTA BARBARA, Calif., June 20, 2017 /PRNewswire/ -- SerImmune Inc. today announced a research and development collaboration agreement with a subsidiary of Merck, known as MSD outside the United States and Canada.
"This collaboration provides strong validation of our immune repertoire characterization platform following Merck's participation in our financing," said Patrick Daugherty, CEO of SerImmune. "We look forward to working with the scientists at Merck, to apply our unique platform to advance Merck's pre-clinical development efforts in infectious diseases."
Under terms of the agreement SerImmune will apply its immune repertoire characterization platform to clinical and preclinical specimens provided by Merck. Merck will lead preclinical and clinical development and commercialization of candidates identified from the collaboration. SerImmune will be eligible to receive development and regulatory milestone payments and tiered royalties on sales of any products resulting from the collaboration.
"The immune system's role in disease continues to be an important area of exploratory research at Merck," said Daria Hazuda, Vice President Infectious Disease Discovery and Chief Scientific Officer, Merck Exploratory Science Center. "This alliance with SerImmune exemplifies our strategy of collaboration with external scientists and entrepreneurs."
About SerImmune Inc.
SerImmune reveals the compositions of functional immune repertoires, creating new opportunities for therapeutic and diagnostic development. SerImmune maps the distinct antibodies within a repertoire to antigens associated with infections, allergens, microbiome organisms, autoimmune diseases, and cancers.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/serimmune-inc-announces-discovery-and-development-collaboration-with-merck-300476637.html
SOURCE SerImmune Inc.